Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

pegrizeprument - Veloxis Pharmaceuticals

Next Previous
Drug Profile

pegrizeprument - Veloxis Pharmaceuticals

Alternative Names: Anti CD28 monoclonal antibody - OSE Therapeutics; FR-104; VEL-101

Latest Information Update: 11 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Effimune
  • Developer Biomedical Primate Research Center; Janssen Biotech; Nantes University Hospital; OSE Immunotherapeutics; Veloxis Pharmaceuticals
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action CD28 antigen inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Transplant rejection
  • No development reported Encephalomyelitis; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Uveitis

Most Recent Events

  • 05 Jun 2024 Adverse events and efficacy data from phase I/II trial in Transplant rejection (In adults, In the elderly) released by company (IV)
  • 11 Dec 2023 Interim safety data from a phase I/II trial in Transplant rejection released by OSE Immunotherapeutics
  • 24 Jul 2023 Veloxis Pharmaceuticals plans a phase II trial in Transplant rejection (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top